MU­NICH — CRISPR Ther­a­peu­tics’ gene edit­ing can­di­date showed mixed dura­bil­i­ty re­sults a year af­ter pa­tients were dosed, ac­cord­ing to ear­ly-stage da­ta pre­sent­ed Fri­day at the an­nu­al …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.